The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
CD105 is important for angiogenesis: evidence and potential applications
Abstract
Angiogenesis is the propelling force for tumor growth and metastasis, and antiangiogenic therapy represents one of the most promising modalities for cancer treatment. CD105 (endoglin) is a proliferation‐associated and hypoxia‐inducible protein abundantly expressed in angiogenic endothelial cells (EC). It is a receptor for transforming growth factor (TGF) ‐β1 and ‐β3 and modulates TGF‐β signaling by interacting with TGF‐β receptors I and/or II. Immunohistochemistry studies have revealed that CD105 is strongly expressed in blood vessels of tumor tissues. Intratumoral microvessel density (MVD) determined using antibodies to CD105 has been found to be an independent prognostic indicator, wherein increased MVD correlates with shorter survival. CD105 is able to be shed into the circulation, with elevated levels detected in patients with various types of cancer and positively correlated with tumor metastasis. Tangible evidence of its proangiogenic role comes from knockout studies in which CD105 null mice die in utero as a result of impaired angiogenesis in the yolk sac and heart defects. The potential usefulness of CD105 for tumor imaging has been evaluated in tumor‐bearing mice and dogs that have shown the rapid accumulation of radiolabeled anti‐CD105 monoclonal antibody in the tumors with a high tumor‐to‐background ratio. The anti‐CD105 antibody conjugated with immunotoxins and immunoradioisotopes efficiently suppressed/abrogated tumor growth in murine models bearing breast and colon carcinoma without any significant systemic side effects. Immunoscintigraphy in patients with renal cell carcinomas has shown specific localization of 99 Tc m ‐labeled CD105 mab in tumor endothelial cells. Thus, CD105 is a promising vascular target that can be used for tumor imaging, prognosis, and bears therapeutic potential in patients with solid tumors and other angiogenic diseases.—Duff, S. E., Li, C., Garland, J. M., Kumar, S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 17, 984–992 (2003)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Cited by
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
TGF-β signaling in vascular biology and dysfunction
Goumans, M.-J., Liu, Z., & ten Dijke, P. (2009) · Cell Research · doi:10.1038/cr.2008.326 · Cited by 601
Biron, K. E., Dickstein, D. L., Gopaul, R., & Jefferies, W. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023789 · Cited by 300
Potential markers of preeclampsia – a review
Grill, S., Rusterholz, C., Zanetti-Dällenbach, R., Tercanli, S., Holzgreve, W., Hahn, S., & Lapaire, O. (2009) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-7-70 · Cited by 293
Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer
Yamamoto, Y., Ibusuki, M., Okumura, Y., Kawasoe, T., Kai, K., Iyama, K., & Iwase, H. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9742-1 · Cited by 151
Metadata
- Authors
- DUFF, S. E., LI, C., GARLAND, J. M., & KUMAR, S.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2003-06
- Volume
- 17
- Issue
- 9
- Pages
- 984-992
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2023949193
- Cited by
- 556
- References
- 1
- FWCI
- 9.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD105 is important for angiogenesis: evidence and potential applications. https://app.cochat.ai/papers/10.1096/fj.02-0634rev
- The paper
- DUFF, S. E., LI, C., GARLAND, J. M., & KUMAR, S. (2003). CD105 is important for angiogenesis: evidence and potential applications. The FASEB Journal. https://doi.org/10.1096/fj.02-0634rev
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
